The Study Advance platform provides direct access to de-identified commercial and claims data from about 89 million patient profiles, allowing for the inclusion of more widely representative patient populations in clinical trials. It also guides researchers through the study design process to reduce the number of needed protocol changes down the line.
“Currently, 80 percent of trials experience delays in recruiting and one out of four amendments were considered completely avoidable,” Rob DiCicco, PharmD, the company’s deputy chief health officer, said in the announcement. “Breakdowns in the clinical trial process, including issues caused by study design decisions, may potentially delay access to life-changing therapies for patients. IBM Study Advance aims to remove the barriers in clinical development to help researchers efficiently bring necessary therapies to patients.”
More articles on health IT:
Don’t be a ‘data pig’ & 2 more ways to maintain trust while collecting patient data
7 alerts, tools hospitals are adding to their EHRs
Study: Family physicians spend up to 33 hours in monthly EHR overtime
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
